A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

2025-523438-24-00 · tracked via the Priya Life Science EU tracker

Sponsor

Ideaya Biosciences Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

01/07/2026

Enrollment target

Sites

France, Spain

Condition studied

DLL3 Expressing Tumors Including Small Cell Lung Cancer

Investigational medicinal product(s)

IDE161IDE849IDE161IMFINZI 50 mg/mL concentrate for solution for infusion

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Safety endpoints: incidence of DLT; incidence and severity of AEs/SAEs (graded based on CTCAE version 5.0); Efficacy endpoints: ORR, CR + PR and DOR per RECIST version 1.1 as assessed by the Investigator

Endpoint detail

Efficacy endpoints: objective response (ORR) and DOR per RECIST version 1.1 • Pharmacokinetic endpoints: blood concentrations and PK parameters of the ADC, total antibody (TAb), and unconjugated payload (IDC-0029701) • Immunogenicity endpoint: anti IDE849 antibody (antidrug antibody [ADA]) incidence and titer

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523438-24-00 on CTIS ↗ ← All trials in the EU